These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 34365846)
41. Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis. Jaques DA; Ponte B; Haidar F; Dufey A; Carballo S; De Seigneux S; Saudan P Nephrol Dial Transplant; 2022 Nov; 37(12):2514-2521. PubMed ID: 35731591 [TBL] [Abstract][Full Text] [Related]
42. Glucose Exposure in Peritoneal Dialysis Is a Significant Factor Predicting Peritonitis. Uiterwijk H; Franssen CFM; Kuipers J; Westerhuis R; Nauta FL Am J Nephrol; 2020; 51(3):237-243. PubMed ID: 32069459 [TBL] [Abstract][Full Text] [Related]
43. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Fried L; Bernardini J; Piraino B Am J Kidney Dis; 2001 Feb; 37(2):337-42. PubMed ID: 11157375 [TBL] [Abstract][Full Text] [Related]
44. Outcome and complications in peritoneal dialysis patients: a five-year single center experience. Alwakeel JS; Alsuwaida A; Askar A; Memon N; Usama S; Alghonaim M; Feraz NA; Shah IH; Wilson H Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):245-51. PubMed ID: 21422621 [TBL] [Abstract][Full Text] [Related]
45. Association Between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: The balANZ Trial. Nataatmadja M; Cho Y; Pascoe EM; Darssan D; Hawley CM; Johnson DW; Perit Dial Int; 2017; 37(4):407-413. PubMed ID: 28408714 [TBL] [Abstract][Full Text] [Related]
46. Effect of body mass index on outcomes of peritoneal dialysis patients in India. Prasad N; Sinha A; Gupta A; Sharma RK; Bhadauria D; Chandra A; Prasad KN; Kaul A Perit Dial Int; 2014 Jun; 34(4):399-408. PubMed ID: 24584600 [TBL] [Abstract][Full Text] [Related]
47. Current status of peritoneal dialysis in Korea: efforts to achieve optimal outcome. Han DS; Hwang JH; Kang DH; Song HY; Noh H; Shin SK; Lee SW; Kang SW; Choi KH; Ha SK; Lee HY Perit Dial Int; 1999; 19 Suppl 3():S17-25. PubMed ID: 10433548 [TBL] [Abstract][Full Text] [Related]
48. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study. Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454 [TBL] [Abstract][Full Text] [Related]
49. Flexibility in peritoneal dialysis prescription: Impact on technique survival. Navaratnarajah A; Clemenger M; McGrory J; Hisole N; Chelapurath T; Corbett RW; Brown EA Perit Dial Int; 2021 Jan; 41(1):49-56. PubMed ID: 32162582 [TBL] [Abstract][Full Text] [Related]
50. [Morbidity and mortality in diabetic patients on peritoneal dialysis. Twenty-five years of experience at a single centre]. Coronel F; Cigarrán S; Herrero JA Nefrologia; 2010; 30(6):626-32. PubMed ID: 21113211 [TBL] [Abstract][Full Text] [Related]
51. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial. Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi MG; Tan SH; Voss D; Perit Dial Int; 2012; 32(5):497-506. PubMed ID: 22991015 [TBL] [Abstract][Full Text] [Related]
52. Single Daily Icodextrin Exchange as Initial and Solitary Therapy. Agar BU; Sloand JA Perit Dial Int; 2018; 38(2):119-124. PubMed ID: 29386305 [TBL] [Abstract][Full Text] [Related]
53. Are USPD patients suitable for incremental peritoneal dialysis: Yes or no? Zhang W; Lv J; Li Y; Liang Y; Sun J Clin Nephrol; 2022 Apr; 97(4):215-225. PubMed ID: 35006069 [TBL] [Abstract][Full Text] [Related]
55. Rationale and Strategies for Preserving Residual Kidney Function in Dialysis Patients. Li T; Wilcox CS; Lipkowitz MS; Gordon-Cappitelli J; Dragoi S Am J Nephrol; 2019; 50(6):411-421. PubMed ID: 31630148 [TBL] [Abstract][Full Text] [Related]
56. Peritoneal dialysis in an ageing population: a 10-year experience. Smyth A; McCann E; Redahan L; Lambert B; Mellotte GJ; Wall CA Int Urol Nephrol; 2012 Feb; 44(1):283-93. PubMed ID: 21537856 [TBL] [Abstract][Full Text] [Related]
57. Incremental peritoneal dialysis allows to reduce the time spent for dialysis, glucose exposure, economic cost, plastic waste and water consumption. Nardelli L; Scalamogna A; Cicero E; Castellano G J Nephrol; 2023 Mar; 36(2):263-273. PubMed ID: 36125629 [TBL] [Abstract][Full Text] [Related]
58. Incremental peritoneal dialysis: Clinical outcomes and residual kidney function preservation. Borràs Sans M; Chacón Camacho A; Cerdá Vilaplana C; Usón Nuño A; Fernández E Nefrologia; 2016; 36(3):299-303. PubMed ID: 27137104 [TBL] [Abstract][Full Text] [Related]
59. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients. Oh KH; Moon JY; Oh J; Kim SG; Hwang YH; Kim S; Lee JS; Ahn C Nephrol Dial Transplant; 2008 Jul; 23(7):2356-64. PubMed ID: 18178604 [TBL] [Abstract][Full Text] [Related]
60. Icodextrin use for peritoneal dialysis in Australia: A cohort study using Australia and New Zealand Dialysis and Transplant Registry. Rangaswamy D; Guddattu V; Webster AC; Borlace M; Boudville N; Clayton P; Badve S; Johnson DW; Sud K Perit Dial Int; 2020 Mar; 40(2):209-219. PubMed ID: 32063201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]